Array BioPharma v. Alembic: Six-Patent MEK Inhibitor Dispute Settles with License
Array BioPharma asserted six US patents covering MEK inhibitor protein kinase compounds and formulations against Alembic’s ANDA in Delaware District Court. After 986 days, the parties reached a settlement and license agreement, with all claims dismissed without prejudice — a resolution that leaves Alembic’s ANDA pathway technically intact.
ANDA Challenge to Array’s MEK Inhibitor Portfolio Ends in Licensed Accord
Array BioPharma Inc. filed suit on September 28, 2022 in the District of Delaware against Alembic Pharmaceuticals Limited and its US affiliate, asserting infringement of six patents — US9314464, US9850229, US10005761, US9562016, US9598376, and US9980944 — covering compounds and compositions as protein kinase inhibitors and MEK inhibitor formulations. The action was a classic Hatch-Waxman ANDA litigation triggered by Alembic’s Paragraph IV certification challenging the patents listed for Array’s MEK inhibitor product.
The case closed on June 10, 2025 via a stipulated order of dismissal without prejudice, underpinned by a private settlement and license agreement. Alembic Pharmaceuticals, Inc. (the US entity) was dismissed early — on September 28, 2022 — leaving Alembic Pharmaceuticals Limited as the remaining defendant. Under the agreed terms, Alembic is prohibited from commercialising its accused ANDA product in the US except as permitted by the license, and the court retains jurisdiction to enforce the settlement. Each party bears its own legal costs.
A 986-day duration suggests substantive litigation activity before settlement, consistent with cases where parties engage in claim construction or early discovery before reaching commercial terms. The dismissal without prejudice and the explicit preservation of Alembic’s Paragraph IV certifications — coupled with FDA’s ability to grant final ANDA approval — indicates the license likely includes a negotiated market-entry date rather than a permanent bar. The precise entry date, royalty structure, and any milestone terms remain confidential and outside the public record.
Filing to Dismissed without Prejudice in 986 days
986 days — above the median for ANDA patent cases in Delaware District Court
Settlement and license secured: what the dismissal order means for both sides
Dismissal without prejudice backed by a private license
A dismissal without prejudice under a stipulated order means no court has adjudicated the merits of infringement or validity. The patents remain presumptively valid and enforceable. Critically, the settlement and license agreement — not the court order — governs Alembic’s commercial rights. The court retains jurisdiction, meaning either party can return to court if the license terms are breached without re-filing from scratch.
No merits rulingArray secures license revenue and product exclusion without trial risk
By settling, Array BioPharma avoids the validity risk inherent in litigating six patents through claim construction and trial. The license agreement generates revenue from Alembic’s future US sales while restricting market entry to agreed conditions. Array’s MEK inhibitor patent portfolio emerges untested and therefore fully enforceable against third parties — a commercially significant outcome given the number of patents asserted.
Portfolio preservedAlembic gains a licensed entry path while retaining ANDA rights
Alembic’s ANDA Paragraph IV certifications are explicitly preserved and FDA may still grant final approval — suggesting the settlement incorporates a future market-entry date rather than blocking Alembic permanently. This is a typical Hatch-Waxman resolution: the generic gains a defined commercial path without bearing the cost and uncertainty of a full trial, while accepting commercialisation restrictions until the license permits entry.
Licensed entry negotiatedSix MEK inhibitor patents remain enforceable against future ANDA filers
Because no claim construction or validity ruling was issued, all six patents retain their full presumption of validity. Any subsequent ANDA filer challenging these patents will face the complete portfolio without the benefit of prior adverse rulings. The settlement signals Array’s willingness to license rather than litigate to judgment, which may inform how future challengers approach negotiation strategy and timing of Paragraph IV certifications.
High re-challenge barFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Array BioPharma, Inc. | Company | Oncology biopharma — holder of six MEK inhibitor composition and formulation patentsSearch in Eureka ↗ |
| Defendant | Alembic | Individual | Indian generic pharmaceutical manufacturer pursuing US ANDA entry for MEK inhibitor productSearch in Eureka ↗ |
| Co-Defendant | Alembic Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Array BioPharma, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Array BioPharma, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Array BioPharma, Inc.Search in Eureka ↗ |
| Defendant counsel | Andrew Peter DeMarco | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant counsel | Johanna Hendriksen | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant counsel | Neil A. Benchell | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant counsel | Timothy Devlin | Attorney | Counsel for AlembicSearch in Eureka ↗ |
| Defendant law firm | Devlin Law Firm LLC | Law Firm | Representing AlembicSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The stipulated order is explicitly stated to ‘not act as an adjudication on the merits,’ preserving the legal status of all six patents in full. The operative commercial terms — including any royalty rate, launch date, or milestone payments — are contained in the private settlement and licence agreement, which is not part of the public record. The order’s retention of court jurisdiction and the restriction on Alembic’s commercialisation activities, subject to licence terms, suggests enforceable performance obligations remain in place post-dismissal.
US9314464, US9850229 and four further patents — MEK inhibitor compounds and formulations
The six patents-in-suit — US9314464, US9850229, US10005761, US9562016, US9598376, and US9980944 — cover compounds and compositions functioning as protein kinase inhibitors, with particular focus on MEK (mitogen-activated protein kinase kinase) inhibition, as well as formulation and preparation claims for MEK inhibitor drug products. Application dates span from US13/931111 through to US15/445393, reflecting a layered patent family built over multiple filing years and designed to protect both the active compound and downstream formulation innovations.
MEK inhibitors occupy a strategically important position in oncology, targeting the RAS-RAF-MEK-ERK signalling pathway implicated in multiple cancers. A portfolio of six patents — spanning composition of matter and formulation claims — creates overlapping layers of protection that a generic manufacturer must navigate entirely to achieve clear FTO. The absence of any adverse claim construction or validity ruling from this case means the full breadth of these patents remains legally intact, heightening risk for any company developing related kinase inhibitor compounds or oncology formulations in the same mechanistic class.
Should your team run an FTO against Array’s MEK inhibitor patent portfolio?
Any company developing MEK inhibitors, related protein kinase inhibitor compounds, or oncology formulations in the RAS-RAF-MEK-ERK pathway should treat this six-patent portfolio as an active enforcement risk. Array demonstrated willingness to assert the full portfolio simultaneously in ANDA litigation, and the absence of any invalidity or non-infringement ruling means each patent’s claim scope is untested. R&D teams advancing IND candidates or formulation programmes in this compound class should commission FTO analysis before preclinical investment scales.
PatSnap Eureka’s FTO Search Agent enables systematic mapping of all six patents — US9314464, US9850229, US10005761, US9562016, US9598376, and US9980944 — against your compound structure, formulation approach, and target indication. Eureka identifies claim-level overlap, flags related family members, and surfaces prior art that could support design-around or challenge strategy, giving IP and R&D teams an actionable risk picture before decisions are locked in.
Run a freedom-to-operate analysis on US9850229B2 to assess your product’s exposure
Run FTO in Eureka →Similar MEK Inhibitor and Kinase Patent ANDA Cases in Delaware
Explore comparable Hatch-Waxman ANDA disputes involving MEK inhibitors, kinase inhibitor compounds, and oncology formulation patents litigated in Delaware District Court.
What this case signals for the MEK inhibitor and oncology patent landscape
Array’s six-patent enforcement strategy and licensed resolution carries clear implications for generic entry timing and portfolio defence in oncology.
Multi-patent ANDA assertions increase settlement leverage significantly
Asserting six patents across compound and formulation claims forces generic challengers to invalidate the entire portfolio to achieve freedom to operate. This stacking strategy, visible here, typically extends litigation timelines and elevates the commercial value of a negotiated licence — making early settlement more attractive for generics.
Preserved Paragraph IV certifications signal a negotiated market-entry date
The explicit preservation of Alembic’s Paragraph IV certifications and FDA approval pathway is a strong indicator that the licence includes a defined launch date. Patent practitioners advising branded clients should treat this structure as a template: grant controlled entry rather than litigate validity to an uncertain conclusion.
Array v Alembic — key questions answered
Array BioPharma asserted six US patents: US9314464, US9850229, US10005761, US9562016, US9598376, and US9980944. These patents cover compounds and compositions as protein kinase inhibitors and formulations comprising a MEK inhibitor, forming a layered portfolio protecting both the active compound and its pharmaceutical preparation.
The case was resolved via a stipulated order of dismissal without prejudice entered June 10, 2025, underpinned by a private settlement and licence agreement. Alembic is restricted from commercialising its accused product in the US except as the licence permits. The specific financial terms, royalty rates, and any agreed market-entry date are confidential and not part of the public court record.
No. The stipulated order explicitly states it ‘shall not act as an adjudication on the merits.’ All six patents retain their full presumption of validity. No claim construction, invalidity finding, or non-infringement ruling was issued, meaning the patents remain legally intact and enforceable at their full asserted scope against other parties.
Yes. The stipulated order explicitly states that nothing prohibits Alembic or its affiliates from maintaining existing Paragraph IV certifications, and FDA retains the ability to grant final ANDA approval. This strongly suggests the settlement includes a negotiated future launch date rather than a permanent market exclusion, consistent with standard Hatch-Waxman settlement structures.
The Delaware District Court, before Judge Gregory B. Williams, retained jurisdiction over both parties specifically for purposes of enforcing the stipulated order of dismissal and the underlying settlement and licence agreement. This means either party may seek court enforcement of the licence terms without filing a new action.
PatSnap Eureka searches patents and litigation data to answer instantly.